10 Stocks To Buy ● [FAST]

AI responses may include mistakes. For financial advice, consult a professional. Learn more My Top 10 Stocks to Buy for 2026 | The Motley Fool

For April 2026, market analysts are highlighting a mix of high-growth technology leaders, undervalued long-term picks, and resilient defensive stocks. Key themes include the sustained expansion of artificial intelligence infrastructure and a strategic shift toward quality companies trading at discounts as the S&P 500 tests new highs. 10 stocks to buy

Analysts at Yahoo Finance view this as a bargain, trading 31% below its 52-week high while maintaining strong growth in Latin American e-commerce and fintech. AI responses may include mistakes

The current investment landscape favors across sectors. While tech stocks have powered much of the market's gains, analysts suggest balancing these with defensive plays like Procter & Gamble (PG) or UnitedHealth Group (UNH) to manage potential volatility from high interest rates or shifting sentiment. Key themes include the sustained expansion of artificial

Despite past volatility, it carries a "Strong Buy" consensus with an average price target of approximately $432 for April 2026, driven by its critical role in cybersecurity.

*As with any medical solution, results may vary from one patient to another, and some patients may not respond to treatment. Please consult a doctor to carefully evaluate the risks and benefits before making your decision.
**Some patients may experience earlier deflation of the Allurion Balloon. The removal of the Allurion Balloon may, in very rare cases, require an endoscopic or surgical intervention. In rare cases, instead of being expelled through the digestive tract, the empty balloon may be vomited out.
***Eligibility for the placement of an Allurion Balloon will be assessed by a certified doctor after an initial consultation and a careful review of your medical history. In the case of an extended Allurion Program, your eligibility is reassessed before each placement to ensure you continue to meet the required conditions.

R. Ienca et al. The procedureless ellipse gastric balloon program: Multicenter experience in 1770 consecutive patients. Obes surg. 2020;30(9):3354-3362. Multicenter, prospective, non-randomized, open registry study conducted in patients with overweight or obesity from January 2016 to June 2019 in 19 international obesity centers participating in the study. A total of 1,770 patients with an average BMI of 34.4 ± 5.3 kg/m2 at baseline underwent treatment with the Elipse swallowable gastric balloon, with a monthly visit and a total follow-up of 4 months. 63 patients (3.6%) did not complete the program, and the balloon was removed before 4 months due to intolerance or other adverse effects.
World Health Organization – Key facts on Obesity and overweight (who.int).
European survey finds over three-quarters of adults with obesity have attempted to lose weight in the past year, but most have been unsuccessful – EASO.
This information is extracted from the instructions for use of the Allurion Gastric Balloon System. Version number CS137-02-ENG. If you have any questions regarding this document, please consult your doctor.
Allurion Presents Data on the Allurion Balloon and AI-Powered Virtual Care Suite with and without GLP-1s to Optimize Muscle Mass and Increase Weight Loss
Allurion Announces Findings from New Studies on Muscle Mass Maintenance in Nearly 20,000 Patients and Four-Year Weight Loss Outcomes at the 2025 Annual Meeting of the ASMBS

Chat with Ally